Publications by authors named "Chengxia Su"
Background: Diarrheal irritable bowel syndrome (IBS-D) is a functional bowel disease with diarrhea, and can be associated with common spleen deficiency syndrome of the prevelent traditional Chinese medicine (TCM) syndrome. Fecal microbiota transplantation (FMT) could help treating IBS-D, but may provide variable effects. Our study evaluated the efficacy of TCM- shenling Baizhu decoction and FMT in treating IBS-D with spleen deficiency syndrome, with significant implications on gut microbiome and serum metabolites.
View Article and Find Full Text PDFArticle Synopsis
- The study compared the effectiveness and safety of a 10-day vonoprazan-amoxicillin (VA) therapy versus a 14-day rabeprazole-amoxicillin (RA) therapy for treating Helicobacter pylori infections in new patients.
- Results showed that the eradication rates were similar, with 89.3% for VA and 84.9% for RA, confirming that VA is non-inferior to RA.
- Compliance was important for treatment success, and using vonoprazan led to a shorter treatment duration and less antibiotic use, making it a preferable option for first-line H. pylori therapy.
Background: This study aimed at investigating the characteristics and correlation between oral (tongue coating) and fecal microbiota in patients with diarrheal irritable bowel syndrome (IBS-D).
Methods: Fifty-two IBS-D patients were chosen, with ten healthy volunteers serving as the normal control group. Tongue coating samples and fecal samples of subjects were sequenced for the 16S rRNA gene (V4-V5).
Article Synopsis
- Antibiotic resistance poses a significant challenge in China, affecting the treatment of infections, necessitating the need for personalized therapies using local data on resistance patterns.* -
- A large multi-center study analyzed 4,242 bacterial strains from gastric biopsy samples across five regions, revealing high resistance rates, especially for clarithromycin, levofloxacin, and metronidazole.* -
- Results showed good agreement between resistant phenotypes and genotypes for clarithromycin and levofloxacin, suggesting that genotype testing could be a viable alternative to traditional methods, while highlighting the importance of ongoing monitoring and personalized treatments.*